In this trial, 342 men with sildenafil-failure ED were given either intranasal PT-141 (10 mg dose) or placebo on demand over ~48 weeks.The outcomes demonstrated a clear benefit of bremelanotide: About 33.5% of men on bremelanotide achieved a positive clinical response (improved erections sufficient for intercourse) compared to only 8.5% on placebo
Compounded versions emerged
Understanding maintenance strategies helps preserve transformation results long-term
Maintenance therapy of choice IQVIAs recent study on 11,431 social media conversations iv suggests that a third of all negative experiences with modern AOMs are due to cost concerns (see Figure 2)
doi: 10.3389/fmolb.2025.1622186 Leri M, Bertolini A, Diaz M and Marongiu R (2025) Editorial: Estrogens and neurodegeneration: a link between menopause and Alzheimers disease in women
Frequently Asked Questions 1STEP Trials Program: Semaglutide 2.4mg for Obesity New England Journal of Medicine, 2021 2SURMOUNT-1: Tirzepatide for Treatment of Obesity New England Journal of Medicine, 2022 3Retatrutide Phase 2 Trial Results in Obesity New England Journal of Medicine, 2023 4Comparative Efficacy of GLP-1 Receptor Agonists: A Network Meta-Analysis The Lancet Diabetes & Endocrinology, 2024 5SELECT Trial: Semaglutide Cardiovascular Outcomes New England Journal of Medicine, 2023 Related Articles Comparison Tirzepatide vs Semaglutide: Which Weight Loss Medication Works Better
